Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Atherosclerosis. 2011 Dec 7;220(2):587–592. doi: 10.1016/j.atherosclerosis.2011.11.038

TABLE 3.

Association of Adiponectin with Adverse Cardiovascular Outcomes After Adjusting for Prognostic Markers.

Log adiponectin per 1-SD increase
HR (95% CI) P value
Model 1a 1.20 (1.08–1.33) 0.0005
Model 2b 1.18 (1.07–1.31) 0.001
Model 3c 1.27 (1.14–1.43) <.0001
Model 4d 1.11 (0.96–1.27) 0.16

Adverse cardiovascular outcomes defined as myocardial infarction, heart failure, or death.

a

Model 1 adjusts for Demographics (age, sex, race).

b

Model 2 adjusts for Model 1 + Clinical Risk Factors (diabetes, eGFR, beta-blocker, aspirin, statin).

c

Model 3 adjusts for Model 2 + Metabolic Markers (BMI, Hemogloblin A1c, insulin, glucose, non-HDL cholesterol, HDL, triglycerides).

d

Model 4 adjusts for Model 3 + measures of baseline cardiac disease severity (LV ejection fraction, diastolic dysfunction, inducible ischemia, log CRP, log NT-proBNP).

Abbreviations: eGFR,estimated glomerular filtration rate; BMI, body mass index; HDL, high-density lipoprotein; LV, left ventricular; CRP, C-reactive protein; NT-proBNP, amino terminal fragment of the prohormone of brain-type natriuretic peptide.